Billiontoone (NASDAQ:BLLN) Stock: Insider Oguzhan Atay Sells 8,333 Shares

Key Points

• CEO Oguzhan Atay sold 8,333 Billiontoone shares at an average price of $120.64, generating approximately $1.01 million. The Rule 10b5-1 transaction reduced his direct ownership by 50% to 8,333 shares.
• BLLN shares fell $11.74 to $106.44, with the company valued at approximately $5.02 billion and trading near the midpoint of its 52-week range. Billiontoone’s latest quarterly results met analyst expectations, with $109.45 million in revenue and $0.15 EPS.
• Analyst sentiment is mixed: seven analysts rate the stock Buy, two Hold, and two Sell, resulting in an overall “Hold” rating and an average price target of $125.88.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) CEO Oguzhan Atay sold 8,333 shares of the business's stock in a transaction on Monday, September 28th. The stock was sold at an average price of $120.64, for a total transaction of $1,005,293.12. Following the transaction, the chief executive officer directly owned 8,333 shares in the company, valued at $1,005,293.12. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total transaction of $321,626.24.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total transaction of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The shares were sold at an average price of $100.32, for a total transaction of $2,507,899.68.
• On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total transaction of $1,717,125.00.
• On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The stock was sold at an average price of $136.95, for a total value of $4,450,875.00.
• On Thursday, July 9th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $126.10, for a total transaction of $1,576,250.00.
• On Monday, July 6th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total transaction of $1,525,625.00.
• On Monday, July 6th, Oguzhan Atay sold 26,250 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total value of $3,203,812.50.

Billiontoone Price Performance

Shares of BLLN traded down $11.74 during trading hours on Wednesday, hitting $106.44. The stock had a trading volume of 968,635 shares, compared to its average volume of 612,070. The stock has a market capitalization of $5.02 billion and a price-to-earnings ratio of 168.83. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. The company's fifty day moving average is $107.92 and its two-hundred day moving average is $99.53. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44.

Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The firm had revenue of $109.45 million during the quarter. On average, analysts anticipate that Billiontoone, Inc. will post 0.83 EPS for the current year.

Hedge Funds Weigh In On Billiontoone

Hedge funds have recently modified their holdings of the stock. MCF Advisors LLC grew its stake in Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company's stock valued at $54,000 after purchasing an additional 344 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Billiontoone during the 2nd quarter worth approximately $29,000. Thrive Wealth Management LLC bought a new stake in shares of Billiontoone during the 2nd quarter worth approximately $240,000. Jasper Ridge Partners L.P. acquired a new stake in shares of Billiontoone in the 2nd quarter valued at approximately $615,000. Finally, Wasatch Advisors LP grew its stake in shares of Billiontoone by 40.2% in the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company's stock valued at $62,160,000 after buying an additional 148,446 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have issued reports on BLLN. Wall Street Zen lowered Billiontoone from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Guggenheim initiated coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a "buy" rating and a $125.00 target price for the company. Weiss Ratings reissued a "sell (d+)" rating on shares of Billiontoone in a research note on Friday, September 18th. JPMorgan Chase & Co. cut their price target on Billiontoone from $145.00 to $130.00 and set an "overweight" rating on the stock in a report on Thursday, August 6th. Finally, BTIG Research decreased their price objective on Billiontoone from $142.00 to $130.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Billiontoone currently has an average rating of "Hold" and an average price target of $125.88.

Billiontoone Company Profile

BillionToOne, Inc NASDAQ: BLLN is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company's platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne's primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.